Porovnat metody
Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.
| Analýza nákladů a přínosů (CBA)× | Analýza dopadu na rozpočet (BIA)× | |
|---|---|---|
| Obor | Ekonomika zdravotnictví | Ekonomika zdravotnictví |
| Rodina | Process / pipeline | Process / pipeline |
| Rok vzniku≠ | 1970s | 2005 |
| Tvůrce≠ | Boardman, Greenberg, and colleagues (welfare economics) | Sullivan, Mauskopf, and colleagues (ISPOR task force) |
| Typ | Method | Method |
| Původní zdroj≠ | Boardman, A. E., Greenberg, D. H., Vining, A. R., & Weimer, D. L. (2018). Cost-Benefit Analysis: Concepts and Practice (5th ed.). Cambridge: Cambridge University Press. link ↗ | Sullivan, S. D., Mauskopf, J. A., Augustovski, F., et al. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14. DOI ↗ |
| Další názvy | CBA, economic appraisal, benefit-cost ratio | BIA, financial impact assessment, budget consequence analysis |
| Příbuzné | 5 | 5 |
| Shrnutí≠ | Cost-benefit analysis compares the total monetary value of benefits produced by a program against its total monetary costs, reporting net present value (NPV) or benefit-cost ratio (BCR). Rooted in welfare economics and used extensively in public policy (transportation, environmental, education, health), CBA answers the question: 'Is this program worth doing from a societal perspective?' Unlike cost-effectiveness analysis, CBA monetizes both costs and benefits, enabling comparison across disparate program types. | Budget impact analysis estimates the financial consequences (net costs or savings) of implementing a new health technology in a specific healthcare system or population over a short time horizon (typically 1–5 years). Distinct from cost-effectiveness analysis (which compares health outcomes per dollar), BIA answers a budgetary question: 'If we adopt this new drug/device, how much will it cost our health system next year?' Widely used by hospital procurement committees, insurance formularies, and government health budgets to assess financial feasibility and reimbursement decision. |
| ScholarGateDatová sada ↗ |
|
|